ImmunityBio, Inc. IBRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.3%-0.5pp | 99.3%-0.7pp | 99.6%-0.4pp | 99.7%-0.3pp | 99.8%-0.2pp | |
| Operating margin | -185.4%+818pp | -226%+2,108pp | -315.8%+4,596pp | -504.2%+27,023pp | -1,003.8%+113,521pp | |
| Net margin | -606.2%+704pp | -310.2%+2,495pp | -422.3%+7,595pp | -648.6%+45,043pp | -1,310.3%+197,684pp | |
| EBITDA margin | -174%+776pp | -212.3%+2,003pp | -296.7%+4,370pp | -475.4%+25,667pp | -949.9%+107,487pp | |
| Free cash flow margin | -212%+995pp | -272.6%+2,427pp | -393.4%+5,527pp | -630.1%+31,909pp | -1,207.2%+135,497pp | |
| Returns | ||||||
| Return on assets | -179.8%-63.7pp | -79.4%+13.8pp | -78.9%+68.6pp | -86.7%+75.8pp | -116.1%+45.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.2× | 0.3×+0.2× | 0.2×+0.2× | 0.1×+0.1× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 6.7×+4.4× | 5.1×+1.7× | 5.8×+3.1× | 4.1×+0.2× | 2.2×-1.4× | |
| Quick ratio | 6.4×+4.3× | 4.9×+1.5× | 5.6×+3.0× | 4×+0.1× | 2×-1.6× | |
| Cash ratio | 3×+1.8× | 1.4×-1.2× | 1.1×-0.8× | 2.7×+0.6× | 1.2×-1.2× | |
| Leverage | ||||||
| Debt-to-assets | 0.7×-0.4× | 0.7×-0.1× | 0.7×-0.2× | 0.8×+0.1× | 1.1×+0.6× | |
| Interest coverage | -5×+1.9× | -5×+3.7× | -5.1×+0.8× | -5.8×-1.5× | -6.9×-3.7× | |
| Per Share | ||||||
| Book value per share | -$0.85-22.2% | -$0.54+22.1% | -$0.55+48.1% | -$0.64+36.8% | -$0.69+32.6% | |
| Valuation | ||||||
| Market capitalization | $7.92B+208% | $1.95B+4.3% | $2.33B-9.0% | $2.46B-43.3% | $2.57B-28.9% | |
| Enterprise value | $8.16B+187% | $2.23B+8.5% | $2.62B-5.0% | $2.63B-41.7% | $2.85B-22.9% | |
| Price / sales | 56.2×-26.1× | 17.2×-110× | 28.2×-320× | 43.5×-3,276× | 82.3×-11,882× | |
| EV / sales | 57.9×-33.2× | 19.7×-120× | 31.8×-345× | 46.5×-3,407× | 91.1×-12,120× | |
| Free cash flow yield | -3.8%+10.9pp | -15.8%+5.5pp | -14%+3.0pp | -14.5%-4.7pp | -14.7%-3.2pp | |
| Earnings yield | -10.8%+5.1pp | -18%+4.1pp | -15%+8.0pp | -14.9%-1.1pp | -15.9%+0.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ImmunityBio, Inc.'s profit margins?
- ImmunityBio, Inc. (IBRX) runs a 99.3% gross margin and a -185.4% operating margin, with a -606.2% net margin.
- Where do ImmunityBio, Inc.'s ratios come from?
- Every ratio is computed from ImmunityBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
